Nicholas Piramal

Nicholas Piramal India Limited (Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical Healthcare company with a presence in the cardio-vascular segment, the antibiotics and respiratory segments, pain management, neuro-psychiatry and anti-diabetics segments and biotechnology. For 2005-06, NPIL's recorded a turnover of Indian Rupee ("Rs") 14,100 million and profits after tax were Rs 1,700 million.

Additional recommended knowledge

Daily Sensitivity Test

Safe Weighing Range Ensures Accurate Results

Daily Visual Balance Check

NPIL's brands in the pharma business are Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67% of the business, while its secondary brands which include Paraxin, Flagyl and Omnatax contribute around 24% of its revenues.

NPIL came into existence in 1988 when it acquired Nicholas Laboratories from Sara Lee and in the last 15 years grown primarily on acquisitions, mergers and alliances. Some of NPIL's acquisitions include the Indian operations of Roche Products Ltd., Boehringer Mannheim India Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc India Ltd., ICI India Ltd.'s Pharma Division and Aventis' Research facilities.

NPIL has joint ventures and alliances with F. Hoffmann-La Roche Ltd., Switzerland; Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK.

NPIL's has a 2,700-strong field force. NPIL, together with its JVs, has 16 strong brands in the Indian Pharma Industry; manufacturing plants - NPIL has plants in Hyderabad and Pithampur.

With the acquisition of Pfizer's Morepeth's manufacturing site in UK, Nicholas Piramal through its wholly owned subsidiary NPIL Pharmaceuticals Limited is a custom manufacturing organization.

NPIL plans to take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan. NPIL major investments in R&D which focus on formulations development, new chemical entity research, clinical research from laboratories in India and abroad. The results till now however have not been very encouraging.

NPIL is the flagship company of the Rs. 25,000 million (US $ 500 million) Piramal Enterprises (PEL). The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.

References

1. India Information on line
2. Financial Statements for FY 2005 Q2